Akhtar Muhammad Sohail, Kousar Farzana, Masood Misbah, Fatimi Shahab
Department of Oncology Bahawalpur Institute of Nuclear Medicine and Oncology (BINO), Bahawalpur.
J Coll Physicians Surg Pak. 2010 Nov;20(11):748-52.
To compare the results of patients with locally advanced breast cancer receiving two different regimens Fluorouracil, Doxorubicin and Cyclophosphamide (FAC) and Paclitaxel and Carboplatin.
Comparative study.
The Oncology Department, Institute of Nuclear Medicine and Oncology (INMOL), Lahore, from March 2007 to September 2008.
Patients with inoperable locally advanced breast cancer of stage were included. Sixteen patients were given FAC regimen and 9 patients were given Paclitaxel and Carboplatin, each combination was cycled after 21 days for four times. Before enrollment, detailed medical histories, physical examinations and performance status assessments were done as well as postchemotherapy evaluation with regular follow-up visits was done. Complete Response (CR, ¯100%) is defined as the disappearance of all known disease parameter i.e. disappearance in detectable tumour size, node free disease and surgery is possible. Partial Response (PR, ¯ > 50%) was defined by 50% or greater decrease in the sum of the areas of bidimensionally measured lesions i.e. change of N2 to N1 or no status and some surgical procedure is possible to downstage the disease. Minor Response (MR) was defined as a decrease in the tumour insufficient to quality for partial response. Static disease or no evaluable reflected no significant change in disease and no evidence of new disease. Progression of disease (> 25%) was defined as a 25% or greater increase in the area of any lesion > 2 cm or in the sum of the products of the individual lesions or the appearance of new malignant lesions, surgery not possible.
Twenty five patients completed neoadjuvant chemotherapy. Sixteen (66%) patients received FAC and 9 (37%) patients received PC chemotherapy. Overall CR (breast and axilla) was 54%, PR was 16% and minor response (MR) was 8%. FAC treatment induced more emesis, mucositis, alopecia and cardiotoxicity. No death occurred.
The Paclitaxel and Carboplatin regimen was better tolerated; both regimens were effective in improving disease and overall survival.
比较局部晚期乳腺癌患者接受两种不同化疗方案（氟尿嘧啶、多柔比星和环磷酰胺（FAC）与紫杉醇和卡铂）的治疗结果。
对比研究。
拉合尔核医学与肿瘤学研究所肿瘤科室，2007年3月至2008年9月。
纳入无法手术的局部晚期乳腺癌患者。16例患者接受FAC方案，9例患者接受紫杉醇和卡铂方案，每种方案每21天循环一次，共进行4次。入组前，详细记录病史、进行体格检查和评估身体状况，化疗后定期随访进行评估。完全缓解（CR，≥100%）定义为所有已知疾病参数消失，即可检测到的肿瘤大小消失、无淋巴结疾病且可行手术。部分缓解（PR，≥＞50%）定义为二维测量病变面积总和减少50%或更多，即从N2变为N1或病情无变化且可行某种手术以降低疾病分期。微小缓解（MR）定义为肿瘤缩小程度不足以达到部分缓解标准。病情稳定或无法评估表示疾病无显著变化且无新疾病证据。疾病进展（＞25%）定义为任何＞2 cm病变面积增加25%或更多，或单个病变乘积之和增加，或出现新的恶性病变且无法进行手术。
25例患者完成新辅助化疗。16例（66%）患者接受FAC方案，9例（37%）患者接受PC化疗。总体完全缓解率（乳腺和腋窝）为54%，部分缓解率为16%，微小缓解率为8%。FAC治疗引起更多呕吐、黏膜炎、脱发和心脏毒性。无死亡病例。
紫杉醇和卡铂方案耐受性更好；两种方案均能有效改善病情和总生存期。
